NVCR as reported
NovoCure Limited reported $674M of revenue over the trailing twelve months, +8.5% on the year before. 10 reported series are charted on this page, each one as filed.
$674M
Revenue, trailing twelve months · to Q1 2026 · +8.5% against the twelve months before
- Net Income
- −$173M
Net Income · +5.4% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$48M
Free Cash Flow · −33% year on year · trailing twelve months to Q1 2026
- Op Margin
- −27%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $674M | +8.5% | Q1 2026 |
| Net Income | −$173M | +5.4% | Q1 2026 |
| EPS | −$1.53 | +1.3% | Q1 2026 |
| Gross Margin | 75% | n/a | Q1 2026 |
| Op Margin | −27% | n/a | Q1 2026 |
| Net Margin | −26% | n/a | Q1 2026 |
| ROE | −48% | n/a | Q1 2026 |
| ROA | −16% | n/a | Q1 2026 |
| ROIC | −26% | n/a | Q1 2024 · 8 quarters behind |
| Free Cash Flow | −$48M | −33% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
NovoCure Limited (NVCR) - Revenue & ProfitRevenue & ProfitNovoCure Limited (NVCR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com